What do cohort studies and meta-analyses find about magnesium intake, brain volume, and cognitive decline in older adults?

No retrieved study directly examined magnesium intake, brain volume, and cognitive decline together in older adults.

The closest evidence here connects magnesium to metabolic and inflammatory pathways that affect brain health. Higher magnesium intake is linked to lower inflammation: women with the highest intake had C-reactive protein (CRP) levels about 0.59 mg/L lower than those with the lowest, and a significant inverse trend across CRP, E-selectin, and sICAM-1 [2][4]. Inflammation drives cognitive decline, and metabolic syndrome—which lower magnesium intake is tied to—raises the odds of cognitive decline by about 42% (OR 1.42) [5]. A 22-year Finnish study found men with magnesium intake above the recommended level had roughly half the epilepsy risk (HR 0.52), a condition with inflammatory links [3].

But those are indirect threads. No study in this retrieval measured brain volume, a direct structural outcome, against magnesium intake. The Australian, Dutch, and UK cohort studies that have looked at this question are absent from this search. What we have shows that magnesium deficiency is common—U.S. adults, especially African American women with a median intake of only 177 mg/day, fall well below the RDA [1]—and that sufficiency correlates with better metabolic and inflammatory profiles known to protect the aging brain.

My call: the evidence is not clear on a direct link between magnesium intake, brain volume, and cognitive decline. The retrieval misses the specific studies that would answer the question. The indirect evidence—lower inflammation and metabolic risk with higher magnesium—is suggestive but insufficient for a conclusion.

Confidence: not clear.